4.34
4.34 (0%)
As of Dec 11, 2024
Lumos Pharma, Inc. [LUMO]
Source:
Company Overview
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. References in this Annual Report to “us,” “we,” “our,” the “Company,” or “Lumos” are to Lumos Pharma, Inc. and its wholly-owned subsidiaries. With our principal executive offices located in Austin, Texas and additional executive and administrative offices located in Ames, Iowa, we are engaged in advancing our clinical program and focused on identifying, acquiring, developing, and commercializing novel products and new therapies for people with rare diseases on a global level, for which there is currently a significant unmet need for safe and effective therapies.
| Country | United States |
| Headquarters | austin, texas |
| Phone Number | (512) 215-2630 |
| Industry | manufacturing |
| CEO | Richard J. Hawkins |
| Website | www.lumos-pharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.7 |
| Operating Profit | $-7.6 |
| Net Income | $-7.5 |
| Net Cash | $-21.6 |
Profit Ratios
| Gross Margin | $0.7 |
| Operating Margin | -1,052.3 |
| Profit as % of Revenues | -9.7% |
| Profit as % of Assets | -82.1% |
| Profit as % of Stockholder Equity | -152% |
Management Effectiveness
| Return on Equity | -152% |
| Return on Assets | -42.8% |
| Turnover Ratio | 8% |
| EBITA | $-7.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $17.5 |
| Total Liabilities | $12.5 |
| Operating Cash Flow | $-24.3 |
| Investing Cash Flow | $1 |
| Financing Cash Flow | $1.7 |
